The EASL Congress 2025 brings together over 8,000 delegates working in the field of hepatology to share the latest advancements in the field.
Poster presentation
Date: Wednesday, 7 May 2025
Time: 8:30
| Multicenter, open-label, randomized non-inferiority study comparing 8-week vs 12-week Sofosbuvir/Ravidasvir treatment for non-cirrhotic chronic hepatitis C patients (EASE trial) Radzi bin Abu Hassan M*, Mohammed NS, Suan MAM, Zulkifli Supramanian D, Jogulu S, Md Salleh MF, Soelar SA, Chan HK |
